Method for screening glioma biomarker based on PTEN gene state

Abstract

The invention provides a method for screening a glioma biomarker based on a PTEN gene state. The method comprises the following steps of: (1) obtaining the PTEN gene states of glioma patients; (2) dividing the glioma patients into a PTENWT subgroup and a PTENmutant subgroup; (3) screening subgroup-specific DEGs for the patients of the subgroups respectively; (4) fitting the subgroup-specific DEGswith the survival time of the subgroup patients to obtain subgroup-specific OPRDEGs; (5) constructing a risk score of each subgroup patient, observing the relationship between the risk score and the malignant degree of the tumor, and predicting the survival rate of each subgroup patient; (6) screening OPRDEGs of independent prognosis of each subgroup; and (7) screening potential targeting drugs. The independent optimal prognostic gene of the PTEN mutation subgroup with high malignant degree is analyzed through multi-factor COX, and further guiding significance is provided for diagnosis, prognostic prediction and treatment of PTEN mutation glioma.

Description

technical field [0001] The invention relates to the field of molecular biology technology and computer, and relates to a method for screening glioma biomarkers based on PTEN gene status. Background technique [0002] Glioma is the most common adult primary brain tumor. Glioma is classified into astrocytoma, oligodendroglioma, and ependymoma according to its histological manifestations. The World Health Organization (WHO) classifies gliomas as Divided into I, II, III and IV grades, the higher the grade, the stronger the invasiveness. Grade IV gliomas, glioblastoma multiforme (GBM), are the most aggressive and high-grade malignant tumors. The 1- and 5-year overall survival rates for high-grade gliomas are 40% and 10%, respectively. The high mortality rate of glioma is due to its aggressiveness and high recurrence rate. The heterogeneity of gliomas did not improve patient survival despite treatment with surgery, radiotherapy, and alkylating chemotherapy. Major advances in g...

AI Technical Summary

Problems solved by technology

[0005] Aiming at the deficiencies of the prior art, the embodiment of the present invention provides a diagnostic biomarker based on different PTEN gene states as stratification criteria to screen different subgroups of glioma prognosis-related biomarkers, and targets the corresponding biomarkers To screen the current therapeutic drugs to solve the heterogeneity caused by PTEN in glioma and the problem that the prognosis of glioma patients cannot be effectively and easily evaluated in the prior art

Images